GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teligent Inc (OTCPK:TLGTQ) » Definitions » 5-Year RORE %

Teligent (Teligent) 5-Year RORE % : 0.00% (As of Jun. 2021)


View and export this data going back to 1997. Start your Free Trial

What is Teligent 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Teligent's 5-Year RORE % for the quarter that ended in Jun. 2021 was 0.00%.

The industry rank for Teligent's 5-Year RORE % or its related term are showing as below:

TLGTQ's 5-Year RORE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.93
* Ranked among companies with meaningful 5-Year RORE % only.

Teligent 5-Year RORE % Historical Data

The historical data trend for Teligent's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teligent 5-Year RORE % Chart

Teligent Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Teligent Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Teligent's 5-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Teligent's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teligent's 5-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teligent's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Teligent's 5-Year RORE % falls into.



Teligent 5-Year RORE % Calculation

Teligent's 5-Year RORE % for the quarter that ended in Jun. 2021 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -3.883--1.6 )/( -27.283-0 )
=-2.283/-27.283
=8.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2021 and 5-year before.


Teligent  (OTCPK:TLGTQ) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Teligent 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Teligent's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Teligent (Teligent) Business Description

Traded in Other Exchanges
N/A
Address
105 Lincoln Avenue, Buena, NJ, USA, 08310
Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.
Executives
Joseph Benesch officer: VP, Controller, PAO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
Alyssa Lozynski officer: Interim CFO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310
William S Marth director 236 GROVE STREET, WELLESLEY MA 02482
Philip K Yachmetz officer: EVP, Chief Legal Off, Corp Sec 501 LAFAYETTE AVE WYCKOFF NJ 07481
R Carter Pate director 5739 WORTHAM LANE, DALLAS TX 75252
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Carole Ben-maimon director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Sabatino Thomas J Jr director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
John E Celentano director C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Steven H Koehler director C/O THE MEDICINES CO, 5 SYLVAN WAY, PARSIPPANY NJ 07054
Keith James officer: Prin Acct Officer Controller 105 LINCOLN AVENUE BUENA NJ 08310
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Donald V Weir 10 percent owner SANDERS MORRIS HARRIS, 600 TRAVIS, HOUSTON TX 77002
Timothy B. Sawyer officer: CEO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310